Kras

Edit

Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors (Erasca Inc)

Public Technologies 13 Jul 2026

At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S ... Erasca is evaluating ERAS-4001 in the BOREALIS-1 Phase 1 trial in patients with KRAS-mutant solid tumors.

Edit

The next KRAS battleground: modelling resistance before the clinic (Champions Oncology Inc)

Public Technologies 09 Jul 2026

) In our previous posts, we explored how KRAS has entered a new era and why benchmarking has become essential for differentiating assets in an increasingly competitive landscape.

Edit

InxMed Announces Publication in The Lancet Respiratory Medicine Featuring Promising Anticancer Activity of Ifebemtinib in combination with Garsorasib in First-Line non-small cell lung cancer (NSCLC) Harboring KRAS G12C Mutation

PR Newswire 09 Jul 2026

InxMed is strategically driving a comprehensive development program for Ifebemtinib across RAS-mutant tumors, with combination regimens already initiated or in preparation not only with KRAS G12C ...

Edit

Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in ...

Times Argus 02 Jul 2026

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul 2, 2026-- ....

Edit

Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer (Genentech Inc)

Public Technologies 02 Jul 2026

The KRAS gene produces the KRAS protein, which acts as a cellular control switch, cycling between an active ("on") and inactive ("off") state to regulate cell growth and ...

Edit

Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer (Roche Holding AG)

Public Technologies 02 Jul 2026

The KRAS gene produces the KRAS protein, which acts as a cellular control switch, cycling between an active ("on") and inactive ("off") state to regulate cell growth and ...

Edit

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer (Roche Holding AG)

Public Technologies 02 Jul 2026

The KRAS gene produces the KRAS protein, which acts as a cellular control switch, cycling between an active ('on') and inactive ('off') state to regulate cell growth and proliferation, making it a ...

Edit

Why Benchmarking is Now Essential in KRAS Drug Development (Champions Oncology Inc)

Public Technologies 29 Jun 2026

) The KRAS landscape has changed. As next-generation inhibitors continue to demonstrate clinical impact, the expectations placed on preclinical programmes are increasing ... [...].

Edit

Beyond the KRAS-Targeted Therapy Breakthrough: Why a New Pancreatic Cancer Drug Matters (City of Hope)

Public Technologies 23 Jun 2026

But the survival benefit is only part of what makes the study so promising, said Vincent Chung, M.D., a medical oncologist at City of Hope . [...] ... Disclaimer.

Edit

KRAS Inhibitors Market is Poised for Robust Growth by 2036 Driven by Expanding KRAS-Targeted Therapies ...

GetNews 23 Jun 2026

The anticipated launch of novel therapies such as Olomorasib, MK-1084, Onvansertib, & other pipeline candidates is expected to transform the KRAS inhibitors treatment landscape and drive substantial market growth through 2036.

Edit

KRAS Has Entered a New Era. Why Your Preclinical Strategy Must Change Now (Champions Oncology Inc)

Public Technologies 19 Jun 2026

) KRAS has long been one of the most important targets in oncology, and for decades it was widely considered "undruggable".

Edit

Anocca has Dosed First Patients with Precision TCR-T Cell Therapy Targeting Mutant KRAS in Pancreatic Cancer

The Milton Standard Journal 11 Jun 2026

SÖDERTÄLJE, Sweden--(BUSINESS WIRE)--Jun 11, 2026-- ....

Edit

GFH375/VS-7375 Granted with FDA's Fast Track Designation for Treatment of KRAS G12D-mutant Unresectable Locally Advanced or Metastatic NSCLC (Apricot Capital)

Public Technologies 08 Jun 2026

The oral KRAS G12D (ON/OFF) inhibitor was previously granted with FDA's FTD for the treatment of [...].

Edit

Identifican un mecanismo que permite a los tumores colorrectales resistir los tratamientos dirigidos a KRAS

Europa Press 05 Jun 2026

Casi la mitad de los pacientes con cáncer colorrectal presentan una mutación en el gen KRAS que provoca que las células normales crezcan y se dividan de forma descontrolada, formando tumores.

Edit

Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines ...

Nasdaq Globe Newswire 03 Jun 2026

– Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naïve colorectal cancer patients – ... .

Podcasts:

Latest News for: kras

Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors (Erasca Inc)

The next KRAS battleground: modelling resistance before the clinic (Champions Oncology Inc)

InxMed Announces Publication in The Lancet Respiratory Medicine Featuring Promising Anticancer Activity of Ifebemtinib in combination with Garsorasib in First-Line non-small cell lung cancer (NSCLC) Harboring KRAS G12C Mutation

Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in ...

Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer (Genentech Inc)

Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer (Roche Holding AG)

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer (Roche Holding AG)

Why Benchmarking is Now Essential in KRAS Drug Development (Champions Oncology Inc)

Beyond the KRAS-Targeted Therapy Breakthrough: Why a New Pancreatic Cancer Drug Matters (City of Hope)

KRAS Inhibitors Market is Poised for Robust Growth by 2036 Driven by Expanding KRAS-Targeted Therapies ...

KRAS Has Entered a New Era. Why Your Preclinical Strategy Must Change Now (Champions Oncology Inc)

Anocca has Dosed First Patients with Precision TCR-T Cell Therapy Targeting Mutant KRAS in Pancreatic Cancer

GFH375/VS-7375 Granted with FDA's Fast Track Designation for Treatment of KRAS G12D-mutant Unresectable Locally Advanced or Metastatic NSCLC (Apricot Capital)

Identifican un mecanismo que permite a los tumores colorrectales resistir los tratamientos dirigidos a KRAS

Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines ...

Article Search

EXPLORE WN.com